1-(4-Ethylthiazol-2-yl)-piperazin | 69389-25-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(4-Ethylthiazol-2-yl)-piperazin
• 英文别名: 1-(4-ethyl-thiazol-2-yl)-piperazine；4-Ethyl-2-piperazin-1-yl-1,3-thiazole
• CAS: 69389-25-9
• 化学式: C₉H₁₅N₃S
• 分子量: 197.304
• InChiKey: RXCQPEGMJILPHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  56.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-Ethylthiazol-2-yl)-piperazin 、 反式-1,2-环己二羧酸酐 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 二氯甲烷 为溶剂， 反应 13.0h， 生成 (1R,2R)-N-(1-cyanocyclopropyl)-2-[4-(4-ethyl-1,3-thiazol-2-yl)piperazine-1-carbonyl]cyclohexane-1-carboxamide
  参考文献：
  名称：

  Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition

  摘要：

  The discovery of nitrile compound 4, a potent inhibitor of Cathepsin K (Cat K) with good bioavailability in dog is described. The compound was used to demonstrate target engagement and inhibition of Cat K in an in vivo dog PD model. The margin to hERG ion channel inhibition was deemed too low for a clinical candidate and an optimisation program to find isosteres or substitutions on benzothiazole group led to the discovery of 20, 24 and 27; all three free from hERG inhibition. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.012
• 作为产物：
  描述：

  t-butyl 4-(4-ethylthiazol-2-yl)piperazine-1-carboxylate 生成 1-(4-Ethylthiazol-2-yl)-piperazin
  参考文献：
  名称：

  Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition

  摘要：

  The discovery of nitrile compound 4, a potent inhibitor of Cathepsin K (Cat K) with good bioavailability in dog is described. The compound was used to demonstrate target engagement and inhibition of Cat K in an in vivo dog PD model. The margin to hERG ion channel inhibition was deemed too low for a clinical candidate and an optimisation program to find isosteres or substitutions on benzothiazole group led to the discovery of 20, 24 and 27; all three free from hERG inhibition. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.012

文献信息

• PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
  申请人：Wang Yihan

  公开号：US20120202776A1

  公开（公告）日：2012-08-09

  The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.

  该发明涉及通式（I）中变量基团如此定义的化合物，以及它们的制备和使用。
• Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition
  作者：Alexander G. Dossetter、Jonathan Bowyer、Calum R. Cook、James J. Crawford、Jonathan E. Finlayson、Nicola M. Heron、Christine Heyes、Adrian J. Highton、Julian A. Hudson、Anja Jestel、Stephan Krapp、Philip A. MacFaul、Thomas M. McGuire、Andrew D. Morley、Jeffrey J. Morris、Ken M. Page、Lyn Rosenbrier Ribeiro、Helen Sawney、Stefan Steinbacher、Caroline Smith

  DOI：10.1016/j.bmcl.2012.07.012

  日期：2012.9

  The discovery of nitrile compound 4, a potent inhibitor of Cathepsin K (Cat K) with good bioavailability in dog is described. The compound was used to demonstrate target engagement and inhibition of Cat K in an in vivo dog PD model. The margin to hERG ion channel inhibition was deemed too low for a clinical candidate and an optimisation program to find isosteres or substitutions on benzothiazole group led to the discovery of 20, 24 and 27; all three free from hERG inhibition. (C) 2012 Elsevier Ltd. All rights reserved.